Interpace Biosciences, Inc.
Interpace Biosciences, Inc., a leading player in the biotechnology sector, is headquartered in the United States, with significant operations across various regions. Founded in 2008, the company has established itself as a pioneer in molecular diagnostics and personalised medicine, focusing on innovative solutions for cancer detection and management. Interpace offers a range of unique products and services, including its proprietary tests that aid in the diagnosis and treatment of thyroid and other cancers. These offerings are distinguished by their ability to provide actionable insights, enhancing patient care and clinical decision-making. With a strong market position, Interpace has achieved notable milestones, including partnerships with healthcare providers and advancements in genomic testing technologies, solidifying its reputation as a trusted resource in the evolving landscape of precision medicine.
DitchCarbon Score
How does Interpace Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Interpace Biosciences, Inc.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Interpace Biosciences, Inc.'s reported carbon emissions
Interpace Biosciences, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to address carbon emissions at this time. Given the absence of emissions data and reduction initiatives, it is unclear how Interpace Biosciences aligns with industry standards for climate action. The company may benefit from developing a comprehensive sustainability strategy that includes measurable targets for emissions reduction and participation in recognised initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As the global focus on climate change intensifies, organisations like Interpace Biosciences are encouraged to adopt transparent reporting practices and set ambitious goals to mitigate their environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Interpace Biosciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
